An analysis of lung screening data led by Brown University researchers helps identify which abnormalities detected outside ...

UroGen Pharma’s fair value estimate holds at US$35.63, with recent model tweaks leaving the price target itself unchanged. Analysts are using recent moves in other healthcare names, where cost ...

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical guidelines for bladder cancer, according to the manufacturer. The National ...

Joining me today are Elizabeth A. Barrett, President and Chief Executive Officer; Mark P. Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Christopher Degnan, Chief ...

Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups At first glance, the findings appear encouraging: CREST and POTOMAC demonstrated modest but statistically ...

A phase III randomised control clinical trial of radiotherapy with radiosensitisation versus intravesical bacillus Calmette-Guerin therapy for high-risk non-muscle invasive bladder cancer: TRAIN.

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts. In this video, Jonathan Rubenstein, MD, a urologist with ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio (IBRX) (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing ...

Current clinical guidelines, including those of the European Association of Urology (EAU), consider a prior NMIBC tumor as a marker for increased risk of future recurrence and progression to ...

Kamat has received research funding from Arquer Diagnostics, EnGene, FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, and SWOG; and ...

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...